Skip to main content
. 2014 Mar 12;3(4):408–418. doi: 10.1016/j.molmet.2014.02.001

Figure 5.

Figure 5

Rosiglitazone and phenformin do not impair mitochondrial ROS production in 3T3L1 adipocytes. (A) Basal and insulin-stimulated (10 nM) glucose uptake in 3T3L1 adipocytes treated with glucose oxidase (Gluc. Ox.; 25 mU/mL) and increasing doses of either rosiglitazone and phenformin; (B) Mitochondrial ROS production via mitosox fluorescence; and (C) Mitochondrial membrane potential (MMP) in 3T3L1 adipocytes treated (24 h) with glucose oxidase and rosiglitazone. (D) Mitochondrial ROS production via mitosox fluorescence; and (E) Mitochondrial membrane potential (MMP) in 3T3L1 adipocytes treated (24 h) with glucose oxidase and phenformin. Data presented as mean ± SEM, n = 3–6 biological replicates. Denotes significantly different from; * vehicle/insulin-treated cells, ‡ glucose oxidase/insulin-treated cells, ∫ glucose oxidase/vehicle-treated cells, ▪ corresponding treatment group/no glucose oxidase treated cells (p < 0.05).